Daily Stock Analysis, GEMP, Gemphire Therapeutics Inc, priceseries

Gemphire Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.35
Close
0.35
High
0.37
Low
0.32
Previous Close
0.32
Daily Price Gain
0.03
YTD High
1.49
YTD High Date
Mar 6, 2019
YTD Low
0.28
YTD Low Date
Oct 10, 2019
YTD Price Change
-0.46
YTD Gain
-56.21%
52 Week High
1.49
52 Week High Date
Dec 4, 2018
52 Week Low
0.28
52 Week Low Date
Oct 10, 2019
52 Week Price Change
-0.84
52 Week Gain
-70.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
8.34
Jan 24. 2017
10.07
12 Trading Days
20.79%
Link
LONG
Mar 20. 2017
10.12
Mar 29. 2017
10.66
7 Trading Days
5.27%
Link
LONG
Jun 28. 2017
12.27
Aug 2. 2017
19.13
24 Trading Days
55.89%
Link
LONG
Aug 28. 2017
8.59
Sep 12. 2017
9.19
10 Trading Days
7.03%
Link
LONG
Jan 18. 2018
7.92
Feb 2. 2018
9.63
11 Trading Days
21.54%
Link
LONG
Mar 1. 2018
7.00
Mar 13. 2018
7.51
8 Trading Days
7.23%
Link
LONG
May 31. 2018
6.20
Jun 11. 2018
6.75
7 Trading Days
8.83%
Link
LONG
Sep 5. 2018
1.57
Sep 25. 2018
2.04
14 Trading Days
29.89%
Link
LONG
Jan 11. 2019
0.89
Jan 29. 2019
1.03
11 Trading Days
15.45%
Link
LONG
Feb 22. 2019
1.18
Mar 8. 2019
1.32
10 Trading Days
11.71%
Link
LONG
Apr 1. 2019
1.19
Apr 12. 2019
1.25
9 Trading Days
5.63%
Link
Company Information
Stock Symbol
GEMP
Exchange
NasdaqGM
Company URL
http://www.gemphire.com
Company Phone
248-980-6538
CEO
Charles L. Bisgaier
Headquarters
Michigan
Business Address
17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA, MI 48152
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001638287
About

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of dyslipidemia. Its product under the Gemcabene name is used an adjunctive therapy to reduce low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and triglycerides. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Northville, MI.

Description

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.